<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607645</url>
  </required_header>
  <id_info>
    <org_study_id>2588.00</org_study_id>
    <secondary_id>NCI-2012-00769</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01607645</nct_id>
  </id_info>
  <brief_title>Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS</brief_title>
  <official_title>Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this study are to learn about the effectiveness, the side-effects, if waiting to
      give the idarubicin and cytarabine may change the side effects or effectiveness, and to
      identify factors to predict for responses to this therapy. The trial will examine combination
      of three chemotherapy drugs. These drugs are decitabine, idarubicin, and cytarabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the morphologic complete remission (CR) rates using a decitabine
      (DAC)-priming followed by idarubicin (IDA) and cytarabine (ARAC) in patients with relapsed or
      refractory acute myeloid leukemia (AML).

      SECONDARY OBJECTIVES:

      I. To determine CR without minimal residual disease (CRMRD-), CR with incomplete blood count
      recovery (CRi), CR with minimal residual disease (CRMRD+), and CR with incomplete blood count
      recovery and with minimal residual disease (CRiMRD+) rates.

      II. To estimate the frequency and severity of regimen-related toxicities.

      III. To identify biomarkers (e.g., deoxyribonucleic acid [DNA] methylation and expression
      changes including interferon regulatory factor [IRF]8) associated with clinical responses.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive decitabine intravenously (IV) over 1 hour on days -4 to 0, cytarabine
      IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.

      ARM II: Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and
      idarubicin as in Arm I.

      In both arms, treatment repeats every 28 days for up to 3 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated early because there were other competing protocols.
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved Morphologic CR</measure>
    <time_frame>Participants were monitored up until the point when they went off study following completion of the treatment (3 months)</time_frame>
    <description>Morphologic complete remission (CR): Absolute Neutrophil Count (ANC)≥1,000/uL, platelet count ≥100,000/uL, &lt;5% Bone Marrow (BM) blasts, no Auer rods (cytoplasmic inclusions which result from an abnormal fusion of the primary (azurophilic) granules), no morphologic dysplasia, and no evidence of extramedullary disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM</measure>
    <time_frame>Assessed for up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine</measure>
    <time_frame>Assessed for up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0</measure>
    <time_frame>Assessed for up to 3 months after completion study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Prolonged Aplasia</measure>
    <time_frame>Assessed for up to 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Severe Neutropenia Defined as an ANC Less Than 500</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Moderate Neutropenia Defined as an ANC Less Than 1000</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000</measure>
    <time_frame>Assessed for up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <arm_group>
    <arm_group_label>Arm1: decitabine, idarubicin, cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2: decitabine, idarubicin, cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm1: decitabine, idarubicin, cytarabine</arm_group_label>
    <arm_group_label>Arm2: decitabine, idarubicin, cytarabine</arm_group_label>
    <other_name>5-aza-dCyd</other_name>
    <other_name>5AZA</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm1: decitabine, idarubicin, cytarabine</arm_group_label>
    <arm_group_label>Arm2: decitabine, idarubicin, cytarabine</arm_group_label>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
    <other_name>DMDR</other_name>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm1: decitabine, idarubicin, cytarabine</arm_group_label>
    <arm_group_label>Arm2: decitabine, idarubicin, cytarabine</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  All patients except those with acute promyelocytic leukemia (APL) who have
             morphological diagnosis of myelodysplastic syndromes (MDS) refractory anemia with
             excess blasts (RAEB)-II or AML by World Health Organization (WHO) diagnostic criteria
             and have either refractory or early relapsed disease; NOTE:

               -  Diagnosis of refractory or relapsed disease must be based on evaluation of a bone
                  marrow (BM) aspirate or peripheral blood (PB) flow cytometry; other standard MDS
                  and AML prognostic studies such as cytogenetics, flow, and molecular testing are
                  highly recommended prior to initiating DAC

               -  A previous BM evaluation or PB flow cytometry from an outside facility are
                  acceptable if the results have been deemed to be adequate for confirming the
                  diagnosis and staging by University of Washington (UW)/Seattle Cancer Care
                  Alliance (SSCA)/Fred Hutchinson Cancer Research Center (FHCRC) review

               -  A BM biopsy is not routinely required but should be obtained if the previous
                  evaluation is not deemed to be adequate for confirming diagnosis and staging by
                  UW/SCCA/FHCRC review

          -  Must have received at least one previous cycle of treatment for myelodysplastic
             syndrome (MDS) or AML and be either refractory as defined as not responded to this
             therapy or in early relapse as defined as developing recurrence of the disease within
             12 months of obtaining a CR

          -  May have previously received demethylating agents (e.g., DAC, 5-azacytidine [5AZA]) or
             histone deacetylases (e.g., suberoylanilide hydroxamic acid) for their MDS or AML if
             these demethylating agents were not used in combination with systemic anthracycline
             and ARAC chemotherapy

          -  May have received hematopoietic growth factors, thalidomide/lenalidomide, signal
             transduction inhibitors, or low dose cytarabine (=&lt; 20 mg/m2/day)

          -  May not have received any therapy for their MDS or AML other than hydroxyurea or
             leukapheresis for at least 14 days prior to start of the first dose of DAC; all
             non-hematologic toxicities must have resolved to &lt; grade 2

          -  Must have a &quot;simplified&quot; treatment-related mortality (TRM) score =&lt; 9.2

          -  Females of childbearing potential must have a negative pregnancy test prior to
             initiation of the protocol therapy; females are considered not of child bearing
             potential if they are surgically sterile (they have undergone a hysterectomy,
             bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal

          -  Females of childbearing potential and males must be willing to use an effective method
             of contraception (hormonal or barrier method of birth control; abstinence) from the
             time consent is signed until 12 weeks after treatment discontinuation

          -  Patients with an active or history of other malignancies are eligible, if their
             projected overall survival for that malignancy is at least 6 months

          -  Prior hormonal therapy such as aromatase inhibitors, selective estrogen receptor
             modulators, estrogen receptor down-regulators, luteinizing hormone-releasing hormone
             (LHRH) agonists and antagonists, and anti-androgens, must be completed at least 30
             days prior to initiation of protocol therapy and must remain off hormonal therapy
             until the patient has finished chemotherapy for their MDS-RAEBII or AML

          -  Direct bilirubin =&lt; 2.5 mg/dL (assessed within 14 days prior to registration) unless
             elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or
             hemolysis

          -  No known hypersensitivity to decitabine (DAC), aracytidine triphosphate (ARAC), or
             idarubicin hydrochloride (IDA)

          -  No clinical evidence of central nervous system (CNS) involvement with leukemia, unless
             a lumbar puncture confirms the absence of leukemic blasts in the cerebrospinal fluid
             (CSF)

          -  No prior positive test for the human immunodeficiency virus (HIV)

          -  No uncontrolled systemic infection

        Exclusion Criteria:

          -  Previous therapy with demethylating agents (e.g., DAC, 5AZA, etc.) or histone
             deacetylases (e.g., suberoylanilide hydroxamic acid, etc.) that was combined with
             daunorubicin (DNR) or IDA and ARAC

          -  Patients with acute promyelocytic leukemia (APL)

          -  Known hypersensitivity to DAC, ARAC, or IDA

          -  Clinical evidence of CNS involvement with leukemia, unless a lumbar puncture confirms
             the absence of leukemic blasts in the CSF

          -  Prior positive test for HIV

          -  Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment)

          -  A &quot;simplified&quot; TRM score &gt; 9.2

          -  Bilirubin &gt; 2.5 mg/dl (assessed within 14 days prior to registration), unless
             elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or
             hemolysis

          -  Patients who have a projected overall survival &lt; 6 months due to malignancies other
             than MDS or AML

          -  Documented symptomatic congestive heart failure or a documented left ventricular
             ejection fraction &lt; 40% assessed by multigated acquisition (MUGA), echocardiography,
             or heart catheterization within 21 days prior to start of decitabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Stirewalt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <results_first_submitted>October 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Derek Stirewalt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant were enrolled between 8/23/12 and 5/16/13 at the FHCRC</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
          <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
          <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
          <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
          <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.75" spread="16.46"/>
                    <measurement group_id="B2" value="34.67" spread="13.01"/>
                    <measurement group_id="B3" value="43.86" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved Morphologic CR</title>
        <description>Morphologic complete remission (CR): Absolute Neutrophil Count (ANC)≥1,000/uL, platelet count ≥100,000/uL, &lt;5% Bone Marrow (BM) blasts, no Auer rods (cytoplasmic inclusions which result from an abnormal fusion of the primary (azurophilic) granules), no morphologic dysplasia, and no evidence of extramedullary disease</description>
        <time_frame>Participants were monitored up until the point when they went off study following completion of the treatment (3 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Morphologic CR</title>
          <description>Morphologic complete remission (CR): Absolute Neutrophil Count (ANC)≥1,000/uL, platelet count ≥100,000/uL, &lt;5% Bone Marrow (BM) blasts, no Auer rods (cytoplasmic inclusions which result from an abnormal fusion of the primary (azurophilic) granules), no morphologic dysplasia, and no evidence of extramedullary disease</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRi-MRD (Minimal Residual Disease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refractory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM</title>
        <time_frame>Assessed for up to 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine</title>
        <time_frame>Assessed for up to Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0</title>
        <time_frame>Assessed for up to 3 months after completion study treatment</time_frame>
        <population>We have analyzed 4 and 3 patients in each arm, respectively. One patient in each of the arms completed 2 cycles of therapy. The numbers provided in the Outcome Measure Data Table in Frequency and Severity of Grade 3, 4, and 5 Toxicities are the numbers of patients with each specified event.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0</title>
          <population>We have analyzed 4 and 3 patients in each arm, respectively. One patient in each of the arms completed 2 cycles of therapy. The numbers provided in the Outcome Measure Data Table in Frequency and Severity of Grade 3, 4, and 5 Toxicities are the numbers of patients with each specified event.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CYCLE 1 : Infection Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 1 : Infection Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 1 : Hepatobiliary Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 1 : Blood and Lymphatic Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 1 : Gastrointenstinal Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 2 : Infection Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 2 : Infection Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 2 : Hepatobiliary Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 2 : Blood and Lymphatic Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYCLE 2 : Gastrointenstinal Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Prolonged Aplasia</title>
        <time_frame>Assessed for up to 45 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Prolonged Aplasia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Severe Neutropenia Defined as an ANC Less Than 500</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <population>No member of Arm II was eligible for evaluation for this Outcome Measure. Therefore, no data was collected for Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Severe Neutropenia Defined as an ANC Less Than 500</title>
          <population>No member of Arm II was eligible for evaluation for this Outcome Measure. Therefore, no data was collected for Arm II.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="25" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Moderate Neutropenia Defined as an ANC Less Than 1000</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <population>No member of Arm II was eligible for evaluation for this Outcome Measure. Therefore, no data was collected for Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Moderate Neutropenia Defined as an ANC Less Than 1000</title>
          <population>No member of Arm II was eligible for evaluation for this Outcome Measure. Therefore, no data was collected for Arm II.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="30" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000</title>
        <time_frame>Assessed for up to 5 years</time_frame>
        <population>No member of Arm II was eligible for evaluation for this Outcome Measure. Therefore, no data was collected for Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
            <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000</title>
          <population>No member of Arm II was eligible for evaluation for this Outcome Measure. Therefore, no data was collected for Arm II.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="18" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Adverse Events were assessed while the participants were receiving study specific treatment for up to 3 months after the start of the treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)</title>
          <description>Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)</title>
          <description>Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
decitabine: Given IV
idarubicin: Given IV
cytarabine: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 4 Infection</sub_title>
                <description>Patient became septic with coag negative Staphylococcus, requiring prolonged hospitalization and IV antibiotics with blood pressure support</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <description>Expected Grade 3 febrile neutropenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Grade 2 abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <description>Grade 1 hemorrhoids</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2 diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <description>One patient with Grade 1; one patient with Grade 2; one patient with Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>2 patients with grade 3 C. difficle; 1 patient with Grade 3 UTI; 1 patient with Grade 3 device related infection; 1 patient with Grade 3 lung infection</description>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <description>One patient developed Grade 2 menorrhagia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <description>Patient developed both, Grade 2 elbow and knee pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Patient developed Grade 1 back pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <description>One patient developed Grade 2 thrombotic event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to similar competing protocol, which made statistical evaluation of primary endpoint and any meaningful evaluation of secondary time points not feasible.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Derek L. Stirewalt</name_or_title>
      <organization>FHCRC</organization>
      <phone>2066675386</phone>
      <email>dstirewa@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

